Table 2.
Transplant characteristics
| Clinical parameter | MSD (n = 1891) | Haplo (n = 413) | p |
|---|---|---|---|
| Conditioning intensity | |||
| Myeloablative conditioning, n (%) | 1574 (83.2%) | 281 (68%) | < 0.0001 |
| Reduced intensity conditioning, n (%) | 317 (16.8%) | 132 (32%) | |
| TBI | |||
| CT | 663 (35.1%) | 237 (57.4%) | < 0.0001 |
| TBI | 1228 (64.9%) | 176 (42.6%) | |
| Graft source | |||
| Bone marrow | 351 (18.6%) | 191 (46.2%) | < 0.0001 |
| Peripheral blood | 1540 (81.4%) | 222 (53.8%) | |
| PTCy | |||
| No PTCy | 1812 (95.8%) | 30 (7.3%) | < 0.0001 |
| PTCy | 79 (4.2%) | 383 (92.7%) | |
| In vivo T-cell depletion | |||
| No ATG | 1537 (81.3%) | 352 (85.2%) | 0.058 |
| ATG | 354 (18.7%) | 61 (14.8%) |
MSD: matched sibling donor, Haplo: haploidentical transplantation, MAC: myeloablative conditioning, RIC: reduced intensity conditioning, TBI: total body irradiation; BM: bone marrow; PB: mobilized peripheral blood stem cells; PTCy: post-transplantation cyclophosphamide; ATG: anti-thymocyte globulin; MAC: myeloablative conditioning; TBI: total body irradiation; CT: chemotherapy; RIC: reduced intensity conditioning